GLP-1 Receptor Agonist Market Report Scope & Overview: The GLP-1 Receptor Agonist Market was estimated at USD 60.6 billion in 2025 and is expected to reach USD 307 billion by 2035 and grow at a CAGR of 17.61% over the forecast period of 2026-2035
The result is a diagnostic system that, despite rapid advances in imaging, fluid biomarkers, and omics sciences, often provides only partial answers
The therapeutic benefits of GLP-1RA go beyond T2D and obesity treatment
We look for the hidden barriers to weight loss, such as: Insulin Resistance: The inability to process sugar efficiently, leading to fat storage
2 Based on more than 31,000 patients in the Kaiser Permanente Medical Weight Management Program in Northern California as of 07-28-2025
Administered as an injectable or liposomal oral liquid